Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations (Unaudited)

v3.26.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Income Statement [Abstract]        
Product Revenue
Product Cost of Sales
Gross Profit
General and Administrative Expenses 1,097,572 967,833 3,630,013 2,703,815
Research and Development Expenses 383,382 356,352 1,130,049 2,775,337
Stock Based Compensation Expenses 860,667 5,343,060 189,490
Franchise Tax Expense 123,654 200,050 343,057 200,050
Series H Warrant Issuance Expenses 264,417 264,417
Transaction Costs Associated with Due Diligence 100,000 100,000
Impairment of Technology License 3,177,999
Loss from Operations (2,565,275) (1,788,652) (13,724,178) (6,133,109)
Other (Income) Expenses        
Interest and Dividend Income (55,477) (35,955) (227,442) (156,042)
Gain on Sale of Investments (24,410) (55,651) (2,176)
Change in fair value of Marketable Securities (2,595) (309) 4,695 1,435
Change in fair value of Derivatives Liabilities (1,541,000) 1,059,000 (2,132,000) (244,000)
Total Other (Income)/Expense (1,623,482) 1,022,736 (2,410,398) (400,783)
Loss Before Income Tax (941,793) (2,811,388) (11,313,780) (5,732,326)
Income Tax Benefit/(Provision)
Net Loss (941,793) (2,811,388) (11,313,780) (5,732,326)
Preferred Stock Dividends & Adjustments 264,243 901,902 473,198 2,691,767
Net Loss Attributable to Common Stockholders $ (1,206,036) $ (3,713,290) $ (11,786,978) $ (8,424,093)
Basic net loss per common share $ (0.14) $ (2.50) $ (1.42) $ (14.77)
Diluted net loss per common share $ (0.14) $ (2.50) $ (1.42) $ (14.77)
Weighted average basic common stock outstanding 8,515,493 1,483,341 8,283,441 570,353
Weighted average diluted common stock outstanding 8,515,493 1,483,341 8,283,441 570,353